The role of CaMKII regulation of phospholamban activity in heart disease by Mattiazzi, Alicia Ramona & Kranias, Evangelina G.
“fphar-05-00005” — 2014/1/24 — 18:51 — page 1 — #1
REVIEW ARTICLE
published: 27 January 2014
doi: 10.3389/fphar.2014.00005
The role of CaMKII regulation of phospholamban activity in
heart disease
Alicia Mattiazzi1 and Evangelia G. Kranias 2*
1 Facultad de Medicina, Centro de Investigaciones Cardiovasculares, Conicet La Plata-Universidad Nacional de La Plata, La Plata, Argentina
2 Department of Pharmacology and Cell Biophysics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA
Edited by:
Donald M. Bers, University of
California at Davis, USA
Reviewed by:
MohamedTrebak, State University of
NewYork, USA
Clemens Möller,
Albstadt-Sigmaringen University,
Germany
*Correspondence:
Evangelia G. Kranias, Department of
Pharmacology and Cell Biophysics,
College of Medicine, University of
Cincinnati, 231 Albert Sabin Way,
Cincinnati, OH, USA
e-mail: kraniaeg@ucmail.uc.edu
Phospholamban (PLN) is a phosphoprotein in cardiac sarcoplasmic reticulum (SR) that
is a reversible regulator of the Ca2+-ATPase (SERCA2a) activity and cardiac contractility.
Dephosphorylated PLN inhibits SERCA2a and PLN phosphorylation, at either Ser16 by PKA
or Thr17 by Ca2+-calmodulin-dependent protein kinase (CaMKII), reverses this inhibition.
Through this mechanism, PLN is a key modulator of SR Ca2+ uptake, Ca2+ load,
contractility, and relaxation. PLN phosphorylation is also the main determinant of β1-
adrenergic responses in the heart. Although phosphorylation ofThr17 by CaMKII contributes
to this effect, its role is subordinate to the PKA-dependent increase in cytosolic Ca2+,
necessary to activate CaMKII. Furthermore, the effects of PLN and its phosphorylation
on cardiac function are subject to additional regulation by its interacting partners, the
anti-apoptotic HAX-1 protein and Gm or the anchoring unit of protein phosphatase 1.
Regulation of PLN activity by this multimeric complex becomes even more important in
pathological conditions, characterized by aberrant Ca2+-cycling. In this scenario, CaMKII-
dependent PLN phosphorylation has been associated with protective effects in both
acidosis and ischemia/reperfusion. However, the beneficial effects of increasing SR Ca2+
uptake through PLN phosphorylation may be lost or even become deleterious, when these
occur in association with alterations in SR Ca2+ leak. Moreover, a major characteristic
in human and experimental heart failure (HF) is depressed SR Ca2+ uptake, associated
with decreased SERCA2a levels and dephosphorylation of PLN, leading to decreased SR
Ca2+ load and impaired contractility. Thus, the strategy of altering SERCA2a and/or PLN
levels or activity to restore perturbed SR Ca2+ uptake is a potential therapeutic tool for HF
treatment. We will review here the role of CaMKII-dependent phosphorylation of PLN at
Thr17 on cardiac function under physiological and pathological conditions.
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INTRODUCTION
A major characteristic of human and experimental heart fail-
ure (HF) is altered Ca2+ cycling, associated with decreased
contractility, which partially reflects the impaired function of
the sarcoplasmic reticulum (SR) membrane. During a normal
excitation-contraction-coupling cycle (ECC), Ca2+ enters the cell
through the L-type Ca2+ channels leading to activation of the
ryanodine receptors (RyR2) in the SR and release of Ca2+ from this
membrane system. This Ca2+-induced-Ca2+-release mechanism
(Fabiato and Fabiato, 1977) underlies a fine-tuned synchroniza-
tion of Ca2+ cycling in the heart, coordinating contraction and
relaxation. Relaxation is mediated mainly by the activity of the SR
Ca2+-ATPase (SERCA2a) and to a lesser extent by the Na+/Ca2+
exchanger (NCX). Thus, the SR is the major regulator of Ca2+-
handling during the cardiac excitation-contraction-relaxation
cycle (Bers, 2001).
The activity of SERCA2a is under the reversible control of
phospholamban (PLN), an SR associated protein (Tada et al.,
1975). PLN is a 52 amino acid phosphoprotein, which, in the
dephosphorylated state, inhibits the apparent Ca2+-affinity of
SERCA2a (James et al., 1989; Kim et al., 1990). PLN can be
phosphorylated at three distinct sites in vitro: Ser16 by cyclic
AMP (cAMP)- and cGMP-dependent protein kinases, Thr17 by
Ca2+-calmodulin-dependent protein kinase II (CaMKII), and
Ser16 by protein kinase C (Movsesian et al., 1984; Simmerman
et al., 1986; Huggins et al., 1989). Phosphorylation of these sites
in vitro relieves the inhibition of PLN on SERCA2a and increases
SR Ca2+ uptake. Whereas Ser10 phosphorylation by PKC does not
occur in intact hearts (Edes and Kranias, 1990), cGMP phospho-
rylation of PLN has been described in isolated myocytes (Bartel
et al., 1995). However, the physiological significance of this path-
way is still unclear. In contrast, phosphorylation of Ser16 and
Thr17 by PKA and CaMKII has been shown to be a key media-
tor of the positive inotropic and relaxant effects of ß1-adrenergic
stimulation in the heart. The increase in SERCA2a activity and
Ca2+ uptake rate elicited by the phosphorylation of these sites,
leads to an increase in the velocity of relaxation, SR Ca2+ load
and SR Ca2+ release which, in association with L-type Ca2+
channel and RyR2 phosphorylation, mediate the enhanced con-
tractility produced by ß1-stimulation (Lindemann et al., 1983;
Lindemann and Watanabe, 1985; Vittone et al., 1990; Napoli-
tano et al., 1992; Mundiña-Weilenmann et al., 1996; Kuschel et al.,
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1999). Dephosphorylation of PLN, occurring by a SR-associated
type 1 phosphatase (PP1; MacDougall et al., 1991), reverses the
activation of SERCA2a and the stimulatory effects of β1-agonists.
This article will discuss the role of Thr17 phosphorylation of PLN
and address its significance under physiological and pathological
processes.
THE PHOSPHOLAMBAN REGULATOME
Phospholamban was first described as a cAMP-dependent pro-
tein kinase substrate in the early 1970s. The phosphorylated
amino acid was shown to be Ser16 and phosphorylation enhanced
SERCA2a activity and Ca2+-uptake (Kirchberger et al., 1972).
Subsequently, PLN was shown to be also phosphorylated by a SR-
associated Ca2+-CaM-kinase (CaMKII) at Thr17 and this phos-
phorylation occurred independently of its PKA-phosphorylation
(Bilezikjian et al., 1981; Davis et al., 1990). Phosphorylation by
CaMKII also enhances SR Ca2+-transport through an increase
in the apparent affinity of the SERCA2a for Ca2+ (KCa). Thus,
it was initially proposed that phosphorylated PLN acts as a
stimulator of cardiac SERCA2a activity. However, in the late
1980s and early 1990s, there were two significant breakthroughs:
(a) in vitro studies of reconstituted SR membrane systems
(James et al., 1989; Kim et al., 1990); and (b) in vivo stud-
ies in mouse models with ablation or overexpression of PLN
(Luo et al., 1994, 1996; Kadambi et al., 1996), which demon-
strated that dephosphorylated PLN is actually an inhibitor of
SERCA2 and phosphorylation relieves this inhibition, giving the
appearance of phosphorylation-induced stimulation. These find-
ings, together with the characterization and identification of a
cardiac SR–associated protein phosphatase that can dephospho-
rylate PLN (Kranias, 1985), has led to our current understanding
of PLN as a reversible inhibitor of cardiac SR Ca2+-ATPase
activity.
Furthermore, recent studies showed that the activity of PLNcan
itself be regulated by the HS-1 associated protein X-1 (HAX-1),
which is ubiquitously expressed in mitochondria and SR. HAX-
1 physically interacts with PLN and the binding region of PLN
includes amino acids 16–22 with both Ser16 and Thr17 phospho-
rylation sites. Interestingly, phosphorylation of PLNdiminishes its
binding to HAX-1, indicating that this interaction may be phys-
iologically relevant in the heart (Vafiadaki et al., 2007). Indeed,
HAX-1 has been found to increase PLN inhibition of SR Ca2+
cycling and cardiac contractility in vivo, whereas β1-adrenergic
stimulation relieves this inhibition (Zhao et al., 2009; Lam et al.,
2013).
Besides HAX-1, other regulatory proteins such as PKA,
CAMKII and PP1 are also associated with PLN, achieving an
efficient and compartmentalized complex that regulates SR Ca2+-
cycling and cardiac function. PP1 is a negative regulator of PLN
activity through its dephosphorylation and increased inhibition
of SERCA2a. Interestingly, the type 1 enzyme is modulated by
its endogenous inhibitors, Inhibitor-1 (I-1) and Inhibitor-2 (I-
2). Inhibitor-1 gets activated upon its PKA phosphorylation at
Thr-35 resulting in potent inhibition of PP1 activity and ampli-
fication of the β1-adrenergic receptor stimulatory effects (Iyer
et al., 1988; Neumann et al., 1991; Gupta et al., 1996). More
recently, the small heat shock protein 20 (Hsp20) was also
identified as a novel interacting partner of PP1 and inhibitor
of its enzymatic activity, resulting in diminished PLN inhibi-
tion and enhanced cardiac function (Qian et al., 2011). Thus,
there is a multimeric functionally coupled signaling complex,
which reversibly regulates SR Ca2+ cycling in the cell, composed
of SERCA, PLN, HAX-1, PKA, CAMKII, PP1, I-1, and Hsp20
(Figure 1).
PHOSPHORYLATION OF PLN BY CaMKII UNDER
PHYSIOLOGICAL CONDITIONS
ß1-ADRENERGIC STIMULATION
It is well established that stimulation by β1-agonists at the cell
membrane, initiates a signal-transduction pathway that involves
the Gs proteins to stimulate cAMP formation by adenylate cyclase,
followed by PKA activation (Figure 2). PKA then phosphory-
lates several proteins in the cardiac myocytes to induce positive
chronotropic, inotropic, and relaxant effects, the so-called“fight or
flight response,”which is considered the most effective mechanism
to acutely increase cardiac output. The underlying phosphopro-
teins include PLN and RyR2 at the SR level, the L-type Ca2+
channel and phospholemman, at the sarcolemma level, and tro-
ponin I (TnI), C protein, and myosin light chain, at the level of the
myofibrils (Bers, 2001).
The role of PLN phosphorylation vs. the phosphorylation of
other proteins, which are also involved in ECC, was demon-
strated by the generation and characterization of gene knockout
and transgenic models with ablation, reduction or overexpres-
sion of PLN in the heart. Ablation of PLN was associated with
enhanced affinity of SERCA2a for Ca2+, contractility and relax-
ation (Luo et al., 1994, 1996). In contrast, overexpression of PLN
decreased Ca2+affinity of SERCA2a and diminished SR Ca2+-
load and cardiac contractility (Kadambi et al., 1996). Importantly,
studies at the cardiomyocyte, organ and intact animal levels
from PLN-deficient mice, indicated a significant attenuation of
the inotropic and lusitropic effects of isoproterenol, compared
FIGURE 1 | Phospholamban regulatome. Scheme of the multimeric
protein complex constituted by SERCA2a, PLN, HAX-1, PKA, CAMKII, PP1,
Inhibitor-1 (I-1), and Hsp20, which reversibly regulates SR Ca2+ transport in
the cell. SERCA2a activity is regulated by its reversible inhibitor PLN and
the histidine rich Ca2+-binding protein (HRC). Phosphorylation of PLN is
mediated by cAMP-dependent protein kinase (PKA) at Ser16 site and
Ca2+-calmodulin-dependent protein kinase (CaMKII) at Thr17 site.
Dephosphorylation of these sites occurs by protein phosphatase 1 (PP1).
The activity of PP1 is regulated by inhibitor-1 (I-1) and Hsp20.
Frontiers in Pharmacology | Pharmacology of Ion Channels and Channelopathies January 2014 | Volume 5 | Article 5 | 2
“fphar-05-00005” — 2014/1/24 — 18:51 — page 3 — #3
Mattiazzi and Kranias CaMKII-regulation of PLN
FIGURE 2 | PKA mediated increase in cytosolic Ca2+ and inhibition of
PP1: two prerequisites for CaMKII-dependent phosphorylation of PLN
during β1-adrenergic stimulation. PKA-dependent phosphorylation of
Ca2+ handling proteins, particularly L-type Ca2+ channel and PLN,
produces an increase in cytosolic Ca2+ that is necessary to activate
CaMKII and produce CaMKII-dependent phosphorylation. PKA also
increases inhibitor-1 and Hsp20 phosphorylation, amplifying the stimulatory
effects of β1–adrenergic stimulation on SR Ca2+-transport, relaxation, and
contractility.
with wild types (Luo et al., 1994; Hoit et al., 1995), and revealed
that PLN is a major mediator of the β1-adrenergic response in
the mammalian heart. However, as noted above, PLN is not
only phosphorylated by PKA, at Ser16, but also by CaMKII at
Thr17, during β1-adrenergic stimulation. These phosphorylations
appear to occur independently of each other in vitro (Bilezikjian
et al., 1981; Davis et al., 1990). However, in vivo attempts to
phosphorylate PLN by CaMKII indicated that an increase in
cAMP levels was a requirement for CaMKII activation (Lin-
demann et al., 1983; Lindemann and Watanabe, 1985; Vittone
et al., 1990; Napolitano et al., 1992; Mundiña-Weilenmann et al.,
1996; Kuschel et al., 1999). This may be due to required PKA-
phosphorylation of PLN, as well as L-type Ca2+ channels and
RyR2, to enhance cytosolic Ca2+, necessary to activate CaMKII.
Indeed the availability of transgenic models, expressing either wild
type PLN (PLN-WT), Ser16 → Ala mutant PLN (PLN-S16A) or
Thr17 → Ala mutant PLN (PLN-T17A) in the cardiac compart-
ment of PLN knockout mice, indicated that the phosphorylation
of Ser16 of PLN is a prerequisite for the phosphorylation of Thr17
(Luo et al., 1998). In addition, these studies showed that Ser16
can be phosphorylated independently of Thr17 in vivo and that
phosphorylation of Ser16 was sufficient for mediating the max-
imal cardiac responses to β1-adrenergic stimulation (Chu et al.,
2000).
The role of CaMKII-phosphorylation of PLN was also
addressed in a model with expression of a CaMKII inhibitory pep-
tide targeted to the longitudinal SR (AIP4-LSR TG; Ji et al., 2006).
The results indicated that Thr17 PLN-phosphorylation as well as
SR Ca2+-uptake and contractile parameters were decreased. How-
ever, the response to isoproterenol remained unaltered. Similarly,
transgenic mice with CaMKII inhibition (AC3-I mice), decreased
SR Ca2+-content without changes in the myocyte response to
isoproterenol (Zhang et al., 2005). These findings suggested a
predominant role of Ser16phosphorylation over that of Thr17 in
the β1-adrenergic response. Furthermore, experiments in per-
fused rat hearts using the PKA inhibitor H-89, confirmed that
PKA activation is required for β1-adreniceptor mediated phos-
phorylation of the Thr17 site in PLN (Said et al., 2002). It was
further demonstrated that, when both PLN phosphorylation sites
are present, the CaMKII site contributes to PLN phosphoryla-
tion and enhanced mechanical effects only at relatively high levels
of β1-adrenergic stimulation, i.e., isoproterenol concentrations
≥10 nM. The lack of contribution of Thr17site to PLN phospho-
rylation at lower isoproterenol concentrations was attributed to
a moderate increase in PKA activity, which would raise intra-
cellular Ca2+ to a level not sufficient to activate CaMKII and
phosphorylate Thr17 site (Mundiña-Weilenmann et al., 1996; Said
et al., 2002). Taken together, these findings support the notion
that CaMKII is a contributor in the stimulatory effects of β1-
adrenergic receptor in the heart. However, PKA activation is
required to create the necessary conditions for CaMKII activa-
tion and Thr17 phosphorylation (Figure 2). A similar conclusion
should hold true for the different Ca2+ handling proteins which
are phosphorylated by both kinases, like L-type Ca2+ chan-
nels or RyR2. Interestingly, sustained β1-adrenergic receptor
stimulation enhanced cell contraction and Ca2+ transients by a
mechanism which is largely PKA-independent but sensitive to
CaMKII-inhibitors. In these studies, a shift from Ser16 to Thr17
phosphorylation pathway was observed, underscoring the role
of CaMKII during prolonged β1-adrenergic stimulation (Wang
et al., 2004). In addition, β1-adrenoceptors activate the guanine
nucleotide exchange protein that is directly activated by cAMP
(Epac), independently of, and in parallel with, PKA. Indeed,
Oestreich et al. (2009) identified RyR2 and PLN as two effec-
tor targets of a pathway mediated by Epac-PLCe-PKCe-CaMKII.
These authors described an increase in Ca2+ transient mainly
attributed to an increase in RyR2 sensitivity by Ca2+ influx acti-
vation. Although the specific role of Thr17 phosphorylation of
PLN in these effects was not directly tested, they showed that β-
adrenergic stimulation-mediated enhancement of SR Ca2+ load
and myoplasmic Ca2+ clearance were not significantly altered by
PLCe ablation, suggesting a poor role of the pathway described, on
SR Ca2+ uptake (Oestreich et al., 2007). Moreover, other results
showed that Epac activation decreases the amplitude of evoked
Ca2+ transient due to Epac-induced SR Ca2+ leak by CaMKIIð-
phosphorylation of RyR2 and SR depletion (Pereira et al., 2007,
2013). The different outcomes of the effects of Epac on Ca2+
transient amplitude may be due to different experimental proto-
cols, since Epac activation produces an initial increase in Ca2+
transients before reaching a steady state, in which Ca2+ transients
are decreased. Yet, both results are consistent with an increase
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in RyR2 activation produced by Epac. The more recent study
by Pereira et al. (2013) further showed that inhibition of PKA-
dependent effects of isoproterenol by H-89 pretreatment blocked
the isoproterenol-induced increase of Ca2+ transient amplitude,
speed of relaxation and SR Ca2+ load. In contrast, isoproterenol
still greatly increased SR Ca2+ spark frequency and decreased
Ca2+ transient amplitude. Both of these effects were similar to the
steady state responses produced by Epac activation. These results
would imply that: (1) most of the isoproterenol-induced PKA-
independent Ca2+ leak enhancement is mediated by Epac; and (2)
the contribution of Epac to isoproterenol–induced SR Ca2+ reup-
take through PLN phosphorylation, is very modest, if any, since
no relaxant effects of isoproterenol could be detected after PKA
inhibition.
PHOSPHORYLATION OF Thr17 OF PLN IN THE ABSENCE OF
β1-ADRENERGIC STIMULATION
As indicated above, several studies showed that CaMKII-
dependent PLN phosphorylation can only occur in the intact
beating heart in the presence of ß1-adrenergic stimulation, while it
occurs independently of cAMP-PKA activation in vitro. To address
this apparent discrepancy, the phosphatase inhibitor okadaic acid
was used in the presence of high extracellular Ca2+. Under
phosphatase inhibition, increasing Ca2+, increased contractility,
relaxation and phosphorylation of Thr17 of PLN, without signifi-
cantly changing either cAMP or Ser16phosphorylation (Mundiña-
Weilenmann et al., 1996). These findings indicated that Thr17 can
be phosphorylated independently of Ser16 of PLN in the intact
heart, in accordance with the in vitro studies. Thus, the relative
balance of protein kinase (PKA and CaMKII) and phosphatase
activities appears to regulate phosphorylation of Thr17 and Ser16
in PLN.
Stimulation frequency (SF), a fundamental physiological mod-
ulator of myocardial performance, is another example in which
Thr17 phosphorylation of PLN can occur in the absence of prior
Ser16 phosphorylation (Hagemann et al., 2000; Zhao et al., 2004;
Valverde et al., 2005). These findings are in concert with the fact
that CaMKII can decode the frequency of Ca2+ spikes into distinct
amounts of kinase activity (De Koninck and Schulman, 1998), and
indicate that SF canproduce a sustained increase inCaMKII,which
leads to the phosphorylation of Thr17 in PLN,without the require-
ment of phosphatase inhibition. Moreover, these results prompted
the link between the observed Thr17 phosphorylation and the
relaxant effect of increasing SF (frequency-dependent acceleration
of relaxation or FDAR,Bers, 2001; Hagemann et al., 2000). Indeed,
FDAR was inhibited in the presence of CaMKII-inhibitors and
in cardiomyocytes expressing the mutant T17A-PLN (Zhao et al.,
2004). However, although the involvement of SR and CaMKII
in FDAR was supported by several studies (Bassani et al., 1995;
DeSantiago et al., 2002; Picht et al., 2007; Wu et al., 2012), a recent
report challenged these previous findings by showing that FDAR
was still present in CaMKIIδ-KO mice (Neef et al., 2013). These
results would suggest that either a CaMKIIδ-independent mecha-
nism or another CaMKII isoform, like CaMKIIγ, is playing a role
in FDAR.
The role of Thr17 phosphorylation of PLN on FDAR was also
questioned on the basis of three main findings: (1) FDAR precedes
the phosphorylation of Thr17 site of PLN (Valverde et al., 2005;
Huke and Bers, 2007); (2) Most studies concur that the main reg-
ulatory effect of PLN phosphorylation is to increase the apparent
Ca2+ affinity of SERCA2a (Simmerman and Jones, 1998), while
FDAR is associated with an increase in the maximal velocity of
SR Ca2+ uptake (Picht et al., 2007); and (3) FDAR has been also
detected in PLNKO mice in one study (DeSantiago et al., 2002),
although this finding was not observed in other studies (Bluhm
et al., 2000; Wu et al., 2012).
Taken together, the underlying molecular steps that encompass
the FDAR process are currently unclear. Although most of the
experimental evidence indicates that CaMKII is involved in FDAR,
some studies have challenged this possibility and the participation
of PLN in FDAR. Thus, it is likely that several rather than a single
mechanism, are associated with this phenomenon.
PHOSPHORYLATION OF PLN BY CaMKII UNDER
PATHOLOGICAL CONDITIONS
ACIDOSIS
Mechanical recovery during acidosis
An understanding of how pH changes alter cardiac function is
important for a better comprehension of some cardiac patho-
logical situations, which are important in the clinical setting.
Myocardial ischemia is particularly relevant along these lines: in
human, acidosis can be detected 15 s after the occlusion of the
coronary artery and is a major mechanism for the loss of contrac-
tility during ischemia (Poole-Wilson, 1989). Substantial changes
in intracellular pH may also occur in disorders of different ori-
gins which affect cardiac function, like sleep apnea/hypopnea
syndrome, diabetic ketoacidosis or in patients on dialysis.
Acidosis produces a rapid decrease in the strength of contrac-
tion (Cingolani et al., 1970; Allen and Orchard, 1983), which is
largely due to a decrease in myofilament Ca2+ responsiveness
(Fabiato and Fabiato, 1978). This decrease displaces Ca2+ from
troponin C, and would be the main mechanism responsible for
the early increase in diastolic Ca2+ during acidosis. The initial
fall in contractility is followed by an increase in the amplitude of
intracellular Ca2+ transients and contractile force (Mattiazzi and
Cingolani, 1977a,b; Allen and Orchard, 1983, the mechanism of
which is not intuitively obvious, because acidosis inhibits most of
the steps of excitation-contraction-coupling (Orchard and Ken-
tish, 1990). Earlier experiments suggested that acidosis-induced
activation of Na+-H+ exchanger (NHE), by increasing cytosolic
Na+ and then Ca2+ through the NCX, was sufficient to over-
come the inhibitory effect of acidosis on SERCA2a, increasing
SR Ca2+ and intracellular Ca2+ transients (Harrison et al., 1992).
However, inhibition of NHE does not always prevent intracellu-
lar Ca2+ and mechanical recovery (Choi et al., 2000; DeSantiago
et al., 2004), indicating that additional mechanisms may play a
role (Figure 3A). A major clue supporting this possibility was
given by experiments showing that Ca2+ and contractile recovery
during acidosis require an intact SR and CaMKII activity, sug-
gesting that CaMKII-dependent phosphorylation at the SR level is
involved in the recovery mechanism (Pérez et al., 1995; Komukai
et al., 2001; Nomura et al., 2002; DeSantiago et al., 2004; Mundiña-
Weilenmann et al., 2005; Neef et al., 2013). Indeed, it was shown
that phosphorylation of theThr17 site of PLN transiently increased
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FIGURE 3 | (A) Intracellular mechanisms that may contribute to the
mechanical recovery during acidosis. Acidosis produces a decrease in
myofilament Ca2+ responsiveness which increases diastolic Ca2+ ([Ca2+]d).
Activation of NHE and direct acidosis inhibition of Na+-Ca2+ exchanger
(NCX), would contribute to the increase in cytosolic Ca2+. Acidosis also
inhibits PP1. The simultaneous increase in cytosolic Ca2+ and inhibition of
PP1 activates CaMKII and enhances PLN phosphorylation at Thr17 site. As a
consequence, there is an increase in SR Ca2+ uptake, able to offset the
direct acidosis-induced inhibition of SERCA2a activity. This would lead to
enhanced SR Ca2+ release and Ca2+ transients, which counteract the
negative effect of acidosis on contractile proteins and supply the substrate for
the slow mechanical recovery during acidosis. (B). Putative intracellular
mechanisms of post-acidosis induced-arrhythmias. Upon returning to control
pH, the inhibitory effects of acidosis are rapidly removed, favoring the
increase in Ca2+ cycling and the contractile recovery towards control levels.
However, the relief of RyR2 from the previous constrain produced by
acidosis, evokes also an increase in diastolic Ca2+ leak from the
(Ca2+-loaded) SR. Such release may activate inward currents through the
NCX, also relieved from the inhibition evoked by acidosis. The inward Na+
current, if large enough, can trigger arrhythmias.
at the onset of acidosis, possibly favored by the increase in intracel-
lular (diastolic) Ca2+ and the inhibition of phosphatase induced
by acidosis (Allen and Orchard, 1983; Vittone et al., 1998). This
phosphorylation was associated with the initial and most sig-
nificant portion of the contractile/relaxation recovery, and both
were blunted by CaMKII-inhibition (Mundiña-Weilenmann et al.,
2005). Thus, CaMKII-dependent PLN phosphorylation provides
a mechanism to overcome the depressant effect of acidosis on
SERCA2a (Mandel et al., 1982). These increases in SR Ca2+ con-
tent and release also counteract the effect of acidosis on contractile
proteins, thereby helping to maintain contractile force. More
recent experiments showed that CaMKII also activatesNHEwhich
may add to the direct activation of the exchanger induced by acido-
sis (Vila-Petroff et al., 2010; Figure 3A). Interestingly, experiments
by DeSantiago et al. (2004) showed absence of mechanical recov-
ery in myocytes lacking PLN (PLNKO). This finding may be taken
to indicate that PLN is essential for SR Ca2+ and mechanical
recovery during acidosis. However, the effects of PLN ablation
mimic maximal PLN phosphorylation. Therefore the results of
DeSantiago et al. (2004) actually raise the question of whether
accelerating SR Ca2+ reuptake during acidosis is beneficial, favor-
ing mechanical recovery as discussed above, or harmful, hindering
it. An explanation to these apparent contradictory results may
lie on the fact that intracellular Ca2+ and mechanical recovery
during acidosis require an increase in SRCa2+ uptake above steady
state, a condition that cannot be accomplished in PLNKO mice in
which basal SR Ca2+ uptake is already at maximal levels. In line
with DeSantiago’s results, Nomura et al. (2002) showed that the
mechanical recovery from acidosis did not occur in highly phos-
phorylated myocytes treated with isoproterenol and a phosphatase
inhibitor.
Acidosis and post-acidosis arrhythmias
The increase in SR Ca2+ load during acidosis, responsible for
the mechanical recovery, may also increase spontaneous SR Ca2+
release and produce extra-systoles (Orchard et al., 1987). More-
over, returning to normal pH after acidosis is also arrhythmogenic:
recovery of pH induces an increase in SR Ca2+ leak. This effect
was attributed to the increase in the opening probability of RyR2
due to the pH increase after acidosis and the acidosis-induced
increase in SR Ca2+ content, still present at the beginning of
post-acidosis (Said et al., 2008). The return to normal pH also
leads to recovery of the previous acidosis-induced inhibition of
NCX (Philipson et al., 1982), favoring Ca2+ extrusion and Na+
gain into the cell, membrane depolarization and eventually trig-
gered arrhythmias (Said et al., 2008; Figure 3B). Together, these
results indicate that post-acidosis CaMKII-dependent DADs are
triggered by two concurrent factors: (1) acidosis-induced increase
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in SR Ca2+ content; and (2) relief of RyR2 and NCX, previously
inhibited by acidosis.
ISCHEMIA/REPERFUSION (I/R)
Stunning
The role of CaMKII in I/R will be addressed in detail elsewhere
in this issue. We will briefly refer here to the role of CaMKII-
dependent PLN phosphorylation in this pathological situation. In
the last few years, a dual effect of CaMKII-dependent protein phos-
phorylation (beneficial and detrimental) has been described in the
scenario of I/R in the intact heart. The beneficial effect of CaMKII
usually refers to the intracellular Ca2+ and contractile recovery
that occurs during stunning, a fully reversible post-ischemic dys-
function (Braunwald and Kloner, 1982). Initially, this beneficial
effect was associated with an increase in the phosphorylation of
Thr17 site in PLN at the onset of reperfusion (Vittone et al., 2002).
Further experiments in transgenic mice in which Thr17 and/or
Ser16 sites of PLN were mutated toAla and direct measurements of
intracellular Ca2+, demonstrated that Thr17 phosphorylation was
essential for the recovery of Ca2+ transients and contractility in the
stunned heart (Said et al., 2003; Valverde et al., 2006). These find-
ings confirmed that the increase in Thr17 phosphorylation of PLN
upon reperfusion, although transient, offers a mechanism that
helps to limit cytosolic Ca2+ overload, by accelerating SR Ca2+
reuptake and thereby ameliorating intracellular Ca2+ handling
(Figure 4). In contrast, when SRCa2+ reuptake is highly enhanced
by ablation of PLN, post-ischemic recovery of contractile function
was negligible (Cross et al., 2003). A possible explanation for this
apparent paradox is the higher ATP consumption of PLNKO
hyperactive hearts relative to WTs, which may greatly influence
contractile recovery. A second possibility that does not exclude the
first one, is that under conditions in which RyR2 are altered, a per-
sistent and exacerbated SR Ca2+ uptake, would greatly elevate SR
Ca2+ content and enhance the propensity for SR Ca2+ leak, which
may conspire against contractile recovery and favor reperfusion
arrhythmias. Indeed, a rise inCaMKII phosphorylation of Ser2814
in RyR2 and an abrupt increase in SR Ca2+ release at the onset
of reflow were recently associated with early reperfusion arrhyth-
mias. This occurs in spite of the fact that Thr17 site of PLN was
also phosphorylated (Said et al., 2011; Valverde et al., 2010). These
results strongly suggest that the beneficial effects of increasing SR
Ca2+ uptake in I/R, may turn to be deleterious under conditions
in which the balance between SR Ca2+ uptake and leak is lost
(Figure 4).
As will be discussed below, this unbalance may constitute a
major cause of the detrimental effect of CaMKII activation in the
irreversible I/R.
Irreversible ischemia/reperfusion
After a prolonged ischemic period, reperfusion evokes irreversible
cardiac injury. Under these conditions, myocytes die by apoptosis,
autophagy and necrosis. The rise in Ca2+ during ischemia and
reperfusion leads to mitochondrial Ca2+ accumulation, which is
greatly favored by the close association between mitochondria and
FIGURE 4 |The beneficial or detrimental effects of CaMKII activation and
PLN phosphorylation in I/R depend on a tight balance between SR Ca2+
reuptake and leak. Reperfusion after a short ischemic period (stunning) is
associated with an increase in CaMKII-dependent PLN and RyR2
phosphorylation. During early reperfusion (A), there is: abrupt release of SR
Ca2+ (inset of the Figure, Valverde et al., 2010), possibly favored by the
ischemia-induced increase in SR Ca2+ content; relief of RyR2 inhibition
exerted by the ischemic acidosis; and increase in Ser2814 phosphorylation of
RyR2 (Said et al., 2011). CaMKII-dependent phosphorylation of PLN does not
counteract SR Ca2+ release, which is partially responsible for early
reperfusion arrhythmias. (B) After the first minutes of reperfusion, the
increase in Thr17 phosphorylation of PLN appears to successfully counteract
SR Ca2+ leak, leading to Ca2+ transients and mechanical
recovery.
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SR and constitutes a main event in the initiation of cell death
(Rizzuto and Pozzan, 2006).
Experimental evidence consistently indicates that CaMKII-
inhibition is protective in the irreversible I/R injury (Zhang et al.,
2005; Vila-Petroff et al., 2007; Salas et al., 2010). Although the
mechanisms for myocardial protection by CaMKII inhibition are
still unclear, the CaMKII deleterious pathway in I/R certainly
involves the SR and the mitochondria (Vila-Petroff et al., 2007;
Salas et al., 2010; Joiner et al., 2012; Valverde et al., 2013). Phos-
phorylation of Thr17, the CaMKII site of PLN, has been shown
to increase at the onset of reperfusion (Vila-Petroff et al., 2007;
Salas et al., 2010). This finding may suggest either that the effect of
PLN phosphorylation is part of the deleterious cascade of CaMKII
activation, or that this phosphorylation is beneficial, although
insufficient to counteract the effect of simultaneous detrimental
mechanisms. The experimental outcome of testing these possibil-
ities has remained controversial. Referent to the first one, Yang
et al. (2006) demonstrated that the protective effect of chronic
CaMKII inhibition in AC3-I mice was lost, when they were inter-
bred with PLNKO mice and submitted to myocardial infarction,
supporting a detrimental effect of enhancing of SR Ca2+ uptake.
Referent to the second possibility, several studies demonstrated
that accelerating SR Ca2+ uptake by different means (i.e., over-
expressing SERCA1a, with higher kinetics than SERCA2a, or
expressing a repressor of PLN activity, PP1 inhibitor-1), alleviated
post-ischemic cardiac injury (Talukder et al., 2007, 2008; Nicolaou
et al., 2009), supporting a beneficial effect of accelerating SR Ca2+
uptake. A possible clue to explain these controversial findings is
given by results showing that proteins, different from PLN, may
be involved in the cascade by which CaMKII activity is deleterious
in I/R. A decrease in the expression of RyR2 has been described
in I/R (Salas et al., 2010), compatible with a degradation/damage
of these channels by the concerted action of calpains and pro-
teasomes (Pedrozo et al., 2010), that would lead to an increase in
the opening probability of RyR2 (Domenech et al., 2003). More-
over, redox alterations or CaMKII-dependent phosphorylation
might also influence the activity of RyR2 and SR Ca2+ leak in I/R
(Hidalgo et al., 2004; Said et al., 2011; Valverde et al., 2013). These
alterations would favor the unbalance between SR Ca2+uptake
and leak, promoting mitochondrial Ca2+ overload and cell death.
This cascade would be further stimulated by the recently described
CaMKII-dependent phosphorylation of mitochondrial Ca2+ uni-
porter (Joiner et al., 2012). Taken together, these findings suggest
that the progression toward a beneficial or detrimental effect of
CaMKII activation and PLN phosphorylation in I/R would criti-
cally depend on the balance between the extent of SR Ca2+ reup-
take and SR Ca2+ leak, largely given by the status/characteristics
of other proteins, also involved in SR Ca2+ handling, like RyR2
(Figure 4).
HEART FAILURE
Heart failure develops when the heart is unable to provide an ade-
quate cardiac output to meet the metabolic needs of the organism.
Mechanical dysfunction and arrhythmias are hallmark features
of HF, being aberrant Ca2+ handling a main cause of these two
characteristic alterations. Indeed, there is evidence supporting a
decrease in intracellular Ca2+-transient and diminished SR Ca2+
content, an outcome that constitutes themajor origin of the altered
contractility in HF (O’Rourke et al., 1999; Piacentino et al., 2003),
and that can be attributed to alterations in the expression/activity
of different Ca2+ regulatory proteins. In particular, a decrease in
SERCA2a and an increase in NCX expressions have been described
in different HF models and species, including human (Hasenfuss,
1998). An enhanced SR Ca2+ leak, through hyperphosphorylated
RyR2, would also contribute to the decrease in SR Ca2+ content
and Ca2+ release, typical of HF (Ai et al., 2005; Shan et al., 2010;
Respress et al., 2012).
The decrease in SERCA2a expression is not associated with
a parallel decrease in PLN, which would produce an increase
in the functional stoichiometry PLN/SERCA, with a decrease in
SERCA2a Ca2+ affinity and SR Ca2+ uptake rate and a pro-
longation of relaxation times (Meyer et al., 1995). Moreover,
phosphorylation of PLN has been found to be decreased, either
at Ser16 (Schwinger et al., 1999; Sande et al., 2002), Thr17 (Net-
ticadan et al., 2000), or both (Huang et al., 1999; Mishra et al.,
2003), accounting for increased inhibition of SERCA2a. These
findings may be due to the attenuation of β1-adrenergic cascade,
due to receptor desensitization, down-regulation and uncou-
pling, typical of the disease progression (Bristow et al., 1982;
Dash et al., 2001; Port and Bristow, 2001), and/or the increase
in PP1 activity, described in HF (Bibb et al., 2001; Carr et al.,
2002; Gupta et al., 2003). Indeed, in human failing myocardium,
phosphorylation of Ser16in PLN decreased because of increases in
PP1 activity (Schwinger et al., 1999), whereas phosphorylation of
Thr17 decreased due to increased activity of PP2B (calcineurin;
Münch et al., 2002). Interestingly, this decrease occurred despite
an increase inCaMKII activity characteristic of HF. Taken together,
these results indicate that the increase in SERCA2a/PLN ratio and
the diminished phosphorylation of PLN, are key determinants
of the depressed SR Ca2+ uptake in HF, leading to an increase
in diastolic Ca2+, a decrease in SR Ca2+ stores and therefore
in Ca2+ available for contraction. This results in reduced con-
tractile force, impaired relaxation and altered force-frequency
relationship.
Given this central role of SERCA2a and PLN in the defective
Ca2+ handling typical of HF, the strategy of altering SERCA2a
and/or PLN levels or activity to restore perturbedCa2+ uptake into
the SR are potential therapeutic strategies for HF treatment (del
Monte and Hajjar, 2003). Indeed, overexpression of SERCA2a can
restore Ca2+ handling and contractile function in animal models
(Cutler et al., 2012) and in human HF (del Monte et al., 1999; Jaski
et al., 2009), suggesting that repairing SERCA2a expression may
be a viable therapy. Moreover PLN ablation prevented HF in a
mouse model of dilated cardiomyopathy caused by deficiency of
the muscle-specific LIM protein (Arber et al., 1997; Minamisawa
et al., 1999). In isolated human HF myocytes, gene therapy with
antisense against PLN improved contractile and diastolic func-
tion (del Monte et al., 2002). In contrast, PLN ablation increased
SR Ca2+ filling and contractility in mice with cardiomyopathy
attributable to overexpression of CaMKII. This led to prema-
ture death and mitochondrial Ca2+ overload, suggesting that
accelerating SR Ca2+ uptake and increasing SR Ca2+ load, is dis-
advantageous at least in the presence of excessive CaMKII activity
(Zhang et al., 2010). These findings are consistent with the idea
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already discussed for I/R: in the face of phosphorylated RyR2
channels, as is the case of CaMKII overexpressing mice, reple-
tion of Ca2+ stores through PLN ablation could further worsen
overall heart function, via mitochondrial Ca2+ loading, cell death,
and arrhythmias.
CONCLUDING REMARKS
We have described that PLN and its CaMKII-dependent phospho-
rylation are part of a multimeric functionally coupled signaling
complex, composed of SERCA, PLN, HAX-1, PKA, CaMKII,
PP1, I-1, and Hsp20, which reversibly regulates SR Ca2+ cycling.
Although CaMKII-dependent PLN phosphorylation contributes
to β1-adrenergic mechanical response, its role is subordinate to
the PKA-dependent increase in cytosolic Ca2+ and inhibition of
phosphatase, necessary to activate CaMKII and phosphorylate
Thr17 of PLN. These requirements are also achieved under differ-
ent pathological situations, like acidosis and I/R, independent of
PKA activation. Under these conditions, CaMKII-dependent PLN
phosphorylation may paradoxically produce either favorable or
harmful cardiac effects. The findings summarized in this review
also suggest that the beneficial or detrimental effects associated
with CaMKII activation and PLN phosphorylation depend on a
tight balance between SR Ca2+ reuptake and leak, determined by
the status/characteristics of other SR proteins, among which the
RyR2 is a main candidate. A moderate or even high increase in SR
Ca2+ uptake (and content) due to PLN phosphorylation, would
enhance RyR2 opening due to the regulatory effect of intra-SR
Ca2+. However, in the absence of additional RyR2 modifications,
the increased SERCA2a activity, produced by PLN phosphoryla-
tion, may cope with the enhanced diastolic SR Ca2+ release/leak.
In contrast, even moderate increases in SR Ca2+ may increase
diastolic SR Ca2+ release under conditions where RyR2 activity
is altered independently of intra-SR Ca2+-induced modifications,
enhancing the propensity to arrhythmias and leading to mito-
chondrial Ca2+ overload, which favors apoptosis and necrosis.
Thus, increasing SERCA2a activity by PLNphosphorylation seems
to have the potential of producing salutary effects in a number
of diseases, as long as these effects are achieved under condi-
tions in which diastolic Ca2+ release is satisfactorily controlled.
Future research in this area is needed to parse the contribution
of different players involved in the balance/interaction between
SR Ca2+ reuptake and leak, including the RyR2 regulators or
the L-type Ca2+ channels. More specifically to the subject of this
review, the recently described multimeric SERCA/PLN-ensemble
may represent a nodal point in the interaction of several pro-
tein partners, regulating and modifying the fine-tuned control
of Ca2+ cycling achieved by the duo SERCA-PLN. An intensive
scrutiny of the various proteins of this new pathway will give new
insights into their role in SR Ca2+ uptake control and may pro-
vide novel therapeutic avenues which can contribute to solve the
abnormalities in Ca2+ handling underlying different pathological
process.
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